Andrew Ko, MD

Andrew Ko, MD

Professor, Department of Medicine (Hematology/Oncology), UCSF

Phone: (415) 353-9888 (appts)
Box 1705, UCSF
San Francisco, CA 94143-1705

UCSF Profiles | Physician Referral Directory

Cancer Center Membership

Program Member » Developmental Therapeutics

Research Summary

My primary clinical and research interests focus on gastrointestinal malignancies, where I have developed and led multiple clinical trials, both within UCSF and across multiple sites nationwide and overseas. I am interested in the development and evaluation of new therapeutic agents ranging from novel cytotoxics to molecular targeted agents to immunotherapies, with a particular emphasis on evaluating these in patients with pancreatic cancer. This work has entailed collaborating with laboratory-based investigators on the correlative/translational science to identify individual patient/tumor characteristics that influence prognosis and response to specific therapies, including both tissue- and blood-based biomarkers. Other university responsibilities include leading the site committee for gastrointestinal cancer-specific clinical trial development at the UCSF HDFCCC and serving as chair of the scientific Protocol Review Committee. Nationally, I have served on the scientific program committee, grants committee, and specialty editorial board for the American Society of Clinical Oncology (ASCO), sit on the editorial board for multiple peer-reviewed oncology journals, and am currently a member of NCI’s Pancreatic Cancer Task Force and the NCCN Pancreatic Cancer guidelines committee.


Brown University, Providence, RI, Sc.B., 1991, Applied Mathematics/Biology
Johns Hopkins School of Medicine, Baltimore, MD, M.D., 1995, Medicine
Board certified, Internal Medicine, 1998
Board certified, Medical Oncology, 2002

Professional Experience

  • 1995-1996
    Beth Israel Hospital (Boston, MA), intern, Department of Internal Medicine
  • 1996-1998
    Beth Israel Hospital (Boston, MA), resident, Department of Internal Medicine
  • 1998-2001
    Stanford University School of Medicine, fellow, Division of Medical Oncology
  • 2001-present
    University of California at San Francisco, Clinical Instructor, Division of Hematology/Oncology
  • 2003-2009
    University of California at San Francisco, Assistant Clinical Professor, Division of Hematology/Oncology
  • 2009-present
    University of California at San Francisco, Associate Professor of Clinical Medicine, Division of Hematology/ Oncology

Honors & Awards

  • 1987
    National Merit Scholarship
  • 1988
    IBM Thomas J. Watson Memorial Scholarship
  • 1990
    Sigma Xi, elected associate member
  • 1991
    Departmental honors and Magna cum laude, Brown University
  • 1993
    Alpha Omega Alpha, student essay competition honoree
  • 1994
    Harry C. Saltzstein Prize in Medical Writing, Johns Hopkins School of Medicine
  • 1995
    Medical Assistance Programs/Reader's Digest International Fellowship
  • 2000
    Amgen National Oncology Fellows' Forum, selected for oral presentation
  • 2000
    American Society of Clinical Oncology, Travel Award (meritorious abstract)
  • 2001
    Digestive Disease Center Collaborative Postdoctoral Fellowship
  • 2003
    UCSF Cancer Center Clinical Investigator Research Program award
  • 2003
    American Society of Clinical Oncology Career Development Award
  • 2007
    Joan Rombauer UCSF Endowed Fellowship
  • 2008
    UCSF Kaiser Award for Excellence in Teaching in the Classroom Setting, nominee
  • 2011
    NCI Cancer Clinical Investigator Team Leadership Award
  • 2013
    UCSF Hematology and Oncology Division Teaching Award

Selected Publications

  1. Ko AH. Striving to Move Beyond Chemotherapy in Advanced Pancreatic Cancer. J Oncol Pract. 2016 Sep; 12(9):808-10.
    View on PubMed
  2. Williams JR, Tenforde MW, Chan JD, Ko A, Graham SM. Safety and clinical response of intraventricular caspofungin for Scedosporium apiospermum complex central nervous system infection. Med Mycol Case Rep. 2016 Sep; 13:1-4.
    View on PubMed
  3. Wang VE, Grandis JR, Ko AH. New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. Clin Cancer Res. 2016 Sep 1; 22(17):4283-90.
    View on PubMed
  4. Ko AH. Raising the bar for the adjuvant treatment of pancreatic cancer. Lancet. 2016 Jul 16; 388(10041):214-5.
    View on PubMed
  5. Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Aug 1; 34(22):2654-68.
    View on PubMed
  6. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Apr; 45(3):370-5.
    View on PubMed
  7. Ko AH. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. Int J Nanomedicine. 2016; 11:1225-35.
    View on PubMed
  8. Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs. 2016 Jun; 34(3):319-28.
    View on PubMed
  9. Ko AH. Pancreatic Cancer and the Possibility of Long-term Survival: A Glimmer of Hope? JAMA Oncol. 2016 Mar 1; 2(3):380-1.
    View on PubMed
  10. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, Van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30.
    View on PubMed
  11. Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016 Apr; 27(4):654-60.
    View on PubMed
  12. Carnevale J, Ko AH. MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Future Oncol. 2016 Feb; 12(4):453-64.
    View on PubMed
  13. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 1; 22(1):61-8.
    View on PubMed
  14. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8.
    View on PubMed
  15. Pollom EL, Koong AC, Ko AH. Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am. 2015 Aug; 29(4):741-59.
    View on PubMed
  16. Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol. 2015 Jun 1; 33(16):1779-86.
    View on PubMed
  17. Walker EJ, Ko AH, Holly EA, Bracci PM. Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer. 2015 Apr 15; 121(8):1287-94.
    View on PubMed
  18. Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Am Soc Clin Oncol Educ Book. 2015; e222-7.
    View on PubMed
  19. Walker EJ, Simko JP, Nakakura EK, Ko AH. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol. 2014 Dec; 5(6):E88-95.
    View on PubMed
  20. Walker EJ, Ko AH, Holly EA, Bracci PM. Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. Int J Cancer. 2015 Mar 15; 136(6):E646-53.
    View on PubMed

Go to UCSF Profiles, powered by CTSI